Table 5. Subgroup analysis according to the IVT patients with and without endovascular therapy.

Clinical outcomes	Patients with endovascular therapy (n = 85)				Patients without endovascular therapy (n = 478)
	Euthyroidism (n = 60)	SHyper (n = 12)	SHypo (n = 13)		Euthyroidism (n = 351)	SHyper (n = 44)	SHypo (n = 83)
Early neurological deterioration
Unadjusted OR (95%CI)	Reference	1.34 (0.36–5.20)	0.23 (0.03–1.91)		Reference	4.02 (1.99–8.14)*	0.72 (0.31–1.66)
Adjusted OR (95%CI)	Reference	1.17 (0.28–4.95)	0.22 (0.03–1.96)		Reference	4.72 (2.08–9.69)*	1.08 (0.44–2.65)
Poor outcome at 3 months
Unadjusted OR (95%CI)	Reference	1.69 (0.19–9.94)	0.25 (0.06–1.04)		Reference	2.50 (1.30–4.83)*	0.85 (0.30–4.83)
Adjusted OR (95%CI)	Reference	1.40 (0.15–9.33)	0.27 (0.08–1.06)		Reference	2.54 (1.21–5.33)*	0.84 (0.49–1.45)
Mortality at 3 months
Unadjusted HR (95%CI)	Reference	2.75 (0.85–6.54)	0.39 (0.04–2.27)		Reference	4.29 (2.63–9.03)*	0.83 (0.29–2.44)
Adjusted HR (95%CI)	Reference	1.77 (0.58–5.44)	0.37 (0.06–2.31)		Reference	3.99 (1.81–9.30)*	0.89 (0.26–3.12)

Abbreviations: CI: confidence interval; OR: odd ratio; HR: hazard ratio; SHyper: subclinical hyperthyroidism; SHypo, subclinical hypothyroidism.

*P < 0.05

Adjusted model was controlled for age, sICH, ASPECTS score at 24 h and vascular occlusion.